http://apiprod.etf.internal.com/private/fund/SBIO/fundreport
SBIO

SBIO

ALPS Medical Breakthroughs ETF
CLOSING PRICECHANGE (%)VOLUME
---- (--)--
>
BZX EXCHANGE CLOSED
LAST TRADECHANGE (%)
---- (--)
BID SIZEBID ($)ASK ($)ASK SIZE
--------
N/A

N/A
  • Overview
  • Efficiency
  • Tradability
  • Fit

SBIO Fund Description

The ALPS Medical Breakthroughs ETF tracks the Poliwogg Medical Breakthroughs Index, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

SBIO Factset Analytics Insight

If you're looking for broad biotech exposure, you won't find it in SBIO; the fund targets biotech companies with drugs in Phase II and Phase III of FDA clinical trials, and limits itself to US-listed firms with market caps between $200M and $5B. SBIO also screens for sustainability—meaning constituent firms have enough cash on hand to last 2 years. Given the low historical success rates in clinical trials, the fund is a high-risk, high-reward bet on a small subset of biotech companies. SBIO's Tradability isn't bad for a specialty fund, with decent volume and sizeable spreads, and its underlying liquidity is good. It charges a middling fee for a niche fund, which may give it an edge over its more expensive rival, BBC.

SBIO MSCI ESG Analytics Insight

The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of October 19, 2017 the ALPS Medical Breakthroughs ETF MSCI ESG Fund Quality Score is 4.31 out of 10.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. SBIO ranks in the 18th percentile within its peer group and in the 15th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage.

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
COMPARE
RESET
Select ETFs to compare their performance:

SBIO Top 10 Countries

SBIO Top 10 Sectors

SBIO Top 10 Holdings View All

SBIO Summary Data

ALPS
12/31/14
Open-Ended Fund
0.5%
$133.48M
$899.9K
0.26%

SBIO Portfolio Data

$3.41B
-9.89
5.16
0.00%
12/20/17
91

SBIO Index Data

Poliwogg Medical Breakthroughs Index
Market Cap
Fundamental
Thomson Reuters US Biotechnology & Medical Research

Related ETFs to SBIO

N/A
Total Return
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max

SBIO Portfolio Management

0.5%
--
--
--

SBIO Tax Exposures

20% / 39.6%
--
Qualified dividends
No

SBIO Fund Structure

Open-Ended Fund
No
Yes
100% / 0%
N/A
N/A
Low
Daily
Bats Book Viewer
TOP OF BOOK
SHARES/SIZEPRICE
ASKS----
----
----
----
----
BIDS----
----
----
----
----
LAST 10 TRADES
TIMEPRICESHARES
15:59:3031.1484
10:02:2031.03100
------
------
------
------
------
------
------
------
Bats BZX Real-time Quote - 23:59:59
Daily Spread
Premium/Discount
Volume

SBIO Factset Analytics Block Liquidity

As of 10/20/17
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of SBIO. SBIO is rated a 5 out of 5.

SBIO Tradability

29,387
$899.9K
22,628
$677.49K
0.26%
$0.08
-0.05%
0.49% / -0.31%
None
100%
50,000
0.45
0.03%
0.19%
722
$31.07
5

SBIO Geographic Exposure

SBIOSegment Benchmark
99.73% 91.41%
-- 3.36%
-- 3.07%
-- 1.79%
-- 0.37%
0.27% --

SBIOSegment Benchmark
99.73% 91.78%
-- 5.15%
0.27% --
99.73% / 0.27% 100.00% / 0.00%

SBIO Performance Statistics

0.74
1.27
1.17
1.36
0.98%
Thomson Reuters US Biotechnology & Medical Research

SBIO MSCI ESG Ratings

4.31 / 10
18.24
15.28
--
0.22%
29.14

SBIO BENCHMARK COMPARISON

    SBIO
    91 Holdings
    Segment Benchmark
    120 Constituents
    Shared Holdings
    45 (Count)
     
    9.89% (Weight)
SBIOSegment Benchmark
73.37% 0.00%
16.95% 47.49%
8.63% 44.75%
1.05% 7.76%
0.90% --